1. Home
  2. |Professionals
  3. |Mark H. Remus

Mark H. Remus

Partner
Partner
bXJlbXVzQGNyb3dlbGwuY29t
VCard
VCard

Areas of Focus

Overview

Clients trust Mark Remus to solve their patent disputes quickly, efficiently, and strategically. He has served as lead counsel on numerous patent infringement litigation matters, and he has successfully represented clients in jury trials, bench trials, and appeals to the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court. Intellectual Asset Management (IAM) magazine writes that Mark is “[a]lways one of the best lawyers in the courtroom, he has an even temperament for litigation and is precise in everything he does,” calling him “quite a force to be reckoned with.” Clients recognize Mark for being “always well-prepared and conscientious” and “tough when the situation requires it.”

Mark has experience with a wide range of technologies, including medical devices, industrial equipment, and electrical components and systems. Mark has extensive experience with pharmaceutical litigation under the Hatch-Waxman Act. He has advised clients on a wide range of drug products and technologies, including new chemical entities, complex formulations, polymorphs, methods of treatment, and extended-release formulations.

Mark consistently has been named by publications and in lists that honor attorney achievement, including the IAM Patent 1000 (2022). Mark has also been recognized as a Leading Life Sciences Lawyer by LMG Life Sciences (2022/2023).

Prior to joining Crowell & Moring, Mark was a shareholder at Brinks Gilson & Lione.

Career & Education

|

    • University of Illinois, B.S., with distinction, chemical engineering, 1994
    • University of Illinois College of Law, J.D., cum laude, 1997
    • University of Illinois, B.S., with distinction, chemical engineering, 1994
    • University of Illinois College of Law, J.D., cum laude, 1997

    • Supreme Court of the United States
    • U.S. Patent and Trademark Office (USPTO)
    • U.S. District Court for the Northern District of Illinois
    • U.S. Court of Appeals for the Federal Circuit
    • U.S. District Court for the Northern District of Illinois, Trial Bar
    • Supreme Court of the United States
    • U.S. Patent and Trademark Office (USPTO)
    • U.S. District Court for the Northern District of Illinois
    • U.S. Court of Appeals for the Federal Circuit
    • U.S. District Court for the Northern District of Illinois, Trial Bar

Mark 's Insights

View All Insights

Representative Matters

  • Led a trial team through a seven-week bench trial that resulted in the district court invalidating a patent on a $1 billion-per-year drug. The district court’s decision was affirmed on appeal.
  • After a two-week jury trial, achieved a complete victory for his patent owner-client on multiple counts of patent and trademark infringement. The district court subsequently found the infringer in contempt of a post-trial injunction and awarded attorney’s fees for willful infringement. The total judgment was over $12 million on just $2 million in accused sales. In awarding attorney’s fees, the district court noted that the “high level of Plaintiffs’ attorneys’ trial practice skills was a significant factor in achieving a favorable result for the Plaintiffs.”
  • Represented numerous pharmaceutical companies in Hatch-Waxman bench trials concerning myriad drugs and technologies.
  • Represented manufacturer in trade secret misappropriation case against a competitor that hired a former employee. The case was successfully resolved when the defendant agreed to redesign the accused products to remove the misappropriated subject matter.
  • On behalf of an industrial equipment manufacturer, successfully persuaded the Federal Circuit to reverse a decision by the Patent Trial and Appeal Board that the challenged patent was valid.
  • In a case that reached the Supreme Court, represented a worldwide offshore drilling contractor in a patent infringement case involving an offshore drilling apparatus. The case made two trips to the Federal Circuit Court of Appeals and then settled on appeal to the Supreme Court after the Court referred the case to the Solicitor General for review and comment.

Mark 's Insights

View All Insights

Recognition

  • Intellectual Asset Management: IAM Patent 1000, 2015 – 2016, 2020–2021; IAM Patent Litigation: Illinois, 2013–2014
  • Euromoney Expert Guide to the World's Leading Patent Law Practitioners, 2017–2020
  • LMG Life Sciences Star, 2013–2020
  • Crain’s: Notable Gen X Leaders in Law, 2019 
  • Illinois Super Lawyers: Intellectual Property Litigation, 2013–2021
  • The Best Lawyers in America: Litigation—Intellectual Property, 2016–2021; Litigation—Patent, 2019–2021
  • Forty Illinois Attorneys Under 40 to Watch, 2006

Mark 's Insights

View All Insights

Insights

Press Coverage | 09.09.24

FTC Backs Teva Orange Book Delisting At Fed. Circ.

Firm News | 8 min read | 08.15.24

The Best Lawyers in America 2025 Recognizes 42 Crowell & Moring Attorneys, Three Selected as Lawyer of the Year

Firm News | 2 min read | 06.06.24

IAM Ranks Crowell & Moring in Patent 1000 2024

Client Alert | 3 min read | 04.23.24

From the Highchair to the Courtroom: Federal Circuit Serves Up Helpful Guidance on Equitable Defenses in Childproof Placemat Patent Dispute
|

View All Insights